Research programme: autologous diabetes cell therapy - Orgenesis

Drug Profile

Research programme: autologous diabetes cell therapy - Orgenesis

Alternative Names: AIP cells - Orgenesis; Autologous insulin producing cells - Orgenesis

Latest Information Update: 20 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tel Hashomer Medical Research Infrastructure and Services
  • Developer Orgenesis
  • Class Cell therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus; Type 1 diabetes mellitus

Most Recent Events

  • 28 Feb 2017 Orgenesis has patent protection for autologous diabetes cell therapy in USA and countries outside the USA (Orgenesis 10-K, February 2017)
  • 28 Feb 2017 Orgenesis has patents pending for autologous diabetes cell therapy in USA, Europe, Australia, Brazil, Canada, China, Eurasia, Israel, Japan, South Korea, Mexico, and Singapore (Orgenesis 10-K, February 2017)
  • 17 Dec 2015 Orgenesis plans a phase I/II trial for Type-1 diabetes mellitus in Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top